RedHill 
Welcome,         Profile    Billing    Logout  
 10 Products   35 Diseases  10 Products   13 Trials   1179 News 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mesupron (upamostat) / RedHill
PROTECT-APT 1, NCT05954286: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Active, not recruiting
2
300
US, RoW
Upamostat, WX-671, RHB-107, Placebo (PO)
Henry M. Jackson Foundation for the Advancement of Military Medicine, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies, RedHill Biopharma Limited, FHI Clinical, Inc.
SARS-CoV-2
05/25
10/25
Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
2016-005199-90: Open Label Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease.

Not yet recruiting
3
100
Europe
RHB-104, Capsule
RedHill Biopharma Ltd., RedHill Biopharma Ltd.
Moderately to Severely Active Crohn's Disease, Crohn's Disease, Diseases [C] - Digestive System Diseases [C06]
 
 
Yeliva (opaganib) / RedHill
NCT03414489: Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

No Longer Available
2a
NA
ABC294640
RedHill Biopharma Limited
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
 
 
ACTRN12624001458527: A study of opaganib in addition to darolutamide in participants with metastatic hormone resistant prostate cancer, selected for the presence of a specific biomarker.

Not yet recruiting
2
60
 
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Ramsay Foundation , Bayer Australia Limited
Prostate Cancer
 
 
RedHill’s_COVID: Initial data shows improvement in Covid-19 with RedHill’s opaganib

Recruiting
2
162
Rest Of World
Yeliva (opaganib) - RedHill
RedHill
Moderate to severe Covid-19
 
 
NCT04207255: Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Completed
2
69
US
Opaganib, Abiraterone, Enzalutamide
Medical University of South Carolina, National Cancer Institute (NCI)
Prostate Cancer
08/23
07/24
Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
2018-000013-20: Study in which the effects of codein and Naloxegol (antidote) on colonic motoric contractions are evaluated Studie waarbij het effect van codeine en Naloxegol (tegenwerkend middel) op de contracties van dikke darm worden geëvalueerd

Ongoing
4
15
Europe
Moventig, Bronchodine, Bisacodyl, Tablet, Syrup, Moventig, Bronchodine, Bisacodyl
KU Leuven, KU Leuven
This study will be performed in healthy volunteers. Dit onderzoek zal worden uitgevoerd in gezonde vrijwilligers., This study will be performed in healthy volunteers. Dit onderzoek zal worden uitgevoerd in gezonde vrijwilligers., Body processes [G] - Physiological processes [G07]
 
 
NaloxegolHRM, NCT05770960: Colonic Motor Patterns in Healthy Volunteers

Completed
4
15
Europe
Naloxegol, Movantik, Moventig, codeine phosphate, Bronchodine, Placebo, Siripus simplex syrup
Universitaire Ziekenhuizen KU Leuven
Opioid-Induced Constipation
05/19
05/19
NCT03235739: Ancillary Effects of Oral Naloxegol (Movantik)

Completed
4
136
US
Naloxegol 25 MG, Movantik, Placebo
The Cleveland Clinic
Pain, Postoperative
05/21
05/22
NCT03523520: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Completed
4
15
US
Methylnaltrexone Bromide 150 mg Oral Tablet, Relistor, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet, Movantik
University of Missouri-Columbia
Constipation Drug Induced
03/23
03/23
2020-000087-26: Time to transit Recovery After treatment with Naloxegol in cardiac Surgery Intensive care Trial Intérêt du Naloxégol dans la reprise du transit en postopératoire de chirurgie cardiaque

Not yet recruiting
3
300
Europe
Tablet, MOVENTIG 12.5 mg et 25 mg
CMC AMBROISE PARE, CMC Ambroise Paré
ileus after cardiac surgery iléus post chirurgie cardiaque, constipation induised by opioïdes after cardiac surgery constipation induite par les opioïdes en poste chirurgie cardiaque, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
2019-000959-14: The NIPA study: A randomized double-blind control clinical trial Naloxegol administration to prevent opioids induced gastrointestinal motility disturbance in brain Injured PAtients. Etude NIPA : Essai contrôlé randomisé en double aveugle évaluant l’administration prophylactique de Naloxegol pour prévenir les troubles de la motilité gastro-intestinale induits par les opioïdes chez les patients cérébrolésés.

Not yet recruiting
3
370
Europe
MOVENTIG® (Naloxégol) 25 mg, Tablet, MOVENTIG® (Naloxégol) 25 mg
CHRU de Brest, Health Ministry
Prevent opioids induced gastrointestinal motility disturbance in brain Injured Patients. Prévention des troubles de la motilité gastro-intestinale induits par les opioïdes chez les patients cérébrolésés., Brain injured patients. Patients cérébrolésés., Diseases [C] - Digestive System Diseases [C06]
 
 
NIPA, NCT05008926: The Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

Recruiting
3
370
Europe
Naloxegol, Placebo
University Hospital, Brest
Brain Injuries
10/25
04/26
NCT03316859: Naloxegol and Opioid-induced Constipation

Recruiting
2/3
280
US
Naloxegol 25 MG, Movantik, Placebo pill
TriHealth Inc.
Constipation, Constipation Drug Induced
12/22
12/22
2015-000419-42: Naloxegol and assessments of opioid induced bowel dysfunction

Ongoing
2
24
Europe
Moventig, OxyContin, Film-coated tablet, Prolonged-release tablet, Moventig, OxyContin
Aalborg University Hospital, Astra Zeneca
Healthy volunteers (Opioid-induced bowel dysfunction), Healthy volunteers (Adverse effects of opioids on the gut), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
NCT03087708: Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Terminated
2
50
US
Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
01/21
04/23
2020-003687-10: To evaluate in patients with opioid induced constipation if the use of Naloxegol may improve gastric emptying rate and gastric symptoms

Not yet recruiting
2
50
Europe
Moventig, Tablet, Moventig
UZLeuven, Kyowa Kirin Holdings BV
Opioid induced gastrointestinal dysfunction, gastrointestinal symptoms caused by opioid intake, Diseases [C] - Digestive System Diseases [C06]
 
 
ANTAGOCYST-01, NCT04219046: Evaluation of Naloxegol in the Prevention of POI After Cystectomy

Not yet recruiting
2
102
NA
Naloxégol oxalate, Naloxegol, Placebo oral tablet, Placebo
Institut Paoli-Calmettes
Bladder Cancer, Cystostomy; Complications
09/22
12/22
NCT02813369: Naloxegol Health Outcome Post Authorisation Safety Study

Terminated
N/A
10000
Europe
naloxegol, non-PAMORA laxative
Kyowa Kirin Pharmaceutical Development Ltd
Opioid Induced Constipation
11/21
11/21
NCT02813356: Naloxegol US PMR CV Safety.

Active, not recruiting
N/A
8800
US
naloxegol, non-PAMORA
Valinor Pharma LLC
Opioid Induced Constipation
12/23
12/23
NCT03720613: Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

Recruiting
N/A
34532
US
Naldemedine, Symproic®, Lubiprostone, Amitiza®, Naloxegol, Movantik®
BioDelivery Sciences International, HealthCore, Inc.
Opioid-induced Constipation
11/30
11/30
Aemcolo (rifamycin SV MMX) / Cosmo Pharma, RedHill, Dr Falk
NCT04501380: Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

Enrolling by invitation
2
30
US
AEMCOLO (Rifamycin SV MMX)
Bradley Connor
Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection
12/22
12/22
RIVET, NCT04082780: Rifamycin in Minimal Hepatic Encephalopathy

Completed
2
30
US
Rifamycin SV MMX, Aemcolo, Placebo
Hunter Holmes Mcguire Veteran Affairs Medical Center
Hepatic Encephalopathy, Cirrhosis, Liver
04/23
04/23
NCT04027894: Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Not yet recruiting
2
142
NA
Rifamycin SV MMX, Rifamycin, Placebo to Rifamycin SV-MMX, Placebo
RedHill Biopharma Limited
Traveler's Diarrhea
01/25
12/25
NCT04026984: Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Not yet recruiting
2
142
NA
Rifamycin SV-MMX, Rifamycin, Placebo
RedHill Biopharma Limited
Traveler's Diarrhea
06/25
12/25
clarithromycin/clofazimine/rifabutin (RHB-204) / RedHill
CleaR-MAC, NCT04616924: RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

Terminated
3
12
US
RHB-204, Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg, Placebo
RedHill Biopharma Limited
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
08/23
08/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mesupron (upamostat) / RedHill
PROTECT-APT 1, NCT05954286: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Active, not recruiting
2
300
US, RoW
Upamostat, WX-671, RHB-107, Placebo (PO)
Henry M. Jackson Foundation for the Advancement of Military Medicine, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies, RedHill Biopharma Limited, FHI Clinical, Inc.
SARS-CoV-2
05/25
10/25
Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
2016-005199-90: Open Label Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease.

Not yet recruiting
3
100
Europe
RHB-104, Capsule
RedHill Biopharma Ltd., RedHill Biopharma Ltd.
Moderately to Severely Active Crohn's Disease, Crohn's Disease, Diseases [C] - Digestive System Diseases [C06]
 
 
Yeliva (opaganib) / RedHill
NCT03414489: Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

No Longer Available
2a
NA
ABC294640
RedHill Biopharma Limited
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
 
 
ACTRN12624001458527: A study of opaganib in addition to darolutamide in participants with metastatic hormone resistant prostate cancer, selected for the presence of a specific biomarker.

Not yet recruiting
2
60
 
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Ramsay Foundation , Bayer Australia Limited
Prostate Cancer
 
 
RedHill’s_COVID: Initial data shows improvement in Covid-19 with RedHill’s opaganib

Recruiting
2
162
Rest Of World
Yeliva (opaganib) - RedHill
RedHill
Moderate to severe Covid-19
 
 
NCT04207255: Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Completed
2
69
US
Opaganib, Abiraterone, Enzalutamide
Medical University of South Carolina, National Cancer Institute (NCI)
Prostate Cancer
08/23
07/24
Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
2018-000013-20: Study in which the effects of codein and Naloxegol (antidote) on colonic motoric contractions are evaluated Studie waarbij het effect van codeine en Naloxegol (tegenwerkend middel) op de contracties van dikke darm worden geëvalueerd

Ongoing
4
15
Europe
Moventig, Bronchodine, Bisacodyl, Tablet, Syrup, Moventig, Bronchodine, Bisacodyl
KU Leuven, KU Leuven
This study will be performed in healthy volunteers. Dit onderzoek zal worden uitgevoerd in gezonde vrijwilligers., This study will be performed in healthy volunteers. Dit onderzoek zal worden uitgevoerd in gezonde vrijwilligers., Body processes [G] - Physiological processes [G07]
 
 
NaloxegolHRM, NCT05770960: Colonic Motor Patterns in Healthy Volunteers

Completed
4
15
Europe
Naloxegol, Movantik, Moventig, codeine phosphate, Bronchodine, Placebo, Siripus simplex syrup
Universitaire Ziekenhuizen KU Leuven
Opioid-Induced Constipation
05/19
05/19
NCT03235739: Ancillary Effects of Oral Naloxegol (Movantik)

Completed
4
136
US
Naloxegol 25 MG, Movantik, Placebo
The Cleveland Clinic
Pain, Postoperative
05/21
05/22
NCT03523520: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Completed
4
15
US
Methylnaltrexone Bromide 150 mg Oral Tablet, Relistor, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet, Movantik
University of Missouri-Columbia
Constipation Drug Induced
03/23
03/23
2020-000087-26: Time to transit Recovery After treatment with Naloxegol in cardiac Surgery Intensive care Trial Intérêt du Naloxégol dans la reprise du transit en postopératoire de chirurgie cardiaque

Not yet recruiting
3
300
Europe
Tablet, MOVENTIG 12.5 mg et 25 mg
CMC AMBROISE PARE, CMC Ambroise Paré
ileus after cardiac surgery iléus post chirurgie cardiaque, constipation induised by opioïdes after cardiac surgery constipation induite par les opioïdes en poste chirurgie cardiaque, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
2019-000959-14: The NIPA study: A randomized double-blind control clinical trial Naloxegol administration to prevent opioids induced gastrointestinal motility disturbance in brain Injured PAtients. Etude NIPA : Essai contrôlé randomisé en double aveugle évaluant l’administration prophylactique de Naloxegol pour prévenir les troubles de la motilité gastro-intestinale induits par les opioïdes chez les patients cérébrolésés.

Not yet recruiting
3
370
Europe
MOVENTIG® (Naloxégol) 25 mg, Tablet, MOVENTIG® (Naloxégol) 25 mg
CHRU de Brest, Health Ministry
Prevent opioids induced gastrointestinal motility disturbance in brain Injured Patients. Prévention des troubles de la motilité gastro-intestinale induits par les opioïdes chez les patients cérébrolésés., Brain injured patients. Patients cérébrolésés., Diseases [C] - Digestive System Diseases [C06]
 
 
NIPA, NCT05008926: The Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

Recruiting
3
370
Europe
Naloxegol, Placebo
University Hospital, Brest
Brain Injuries
10/25
04/26
NCT03316859: Naloxegol and Opioid-induced Constipation

Recruiting
2/3
280
US
Naloxegol 25 MG, Movantik, Placebo pill
TriHealth Inc.
Constipation, Constipation Drug Induced
12/22
12/22
2015-000419-42: Naloxegol and assessments of opioid induced bowel dysfunction

Ongoing
2
24
Europe
Moventig, OxyContin, Film-coated tablet, Prolonged-release tablet, Moventig, OxyContin
Aalborg University Hospital, Astra Zeneca
Healthy volunteers (Opioid-induced bowel dysfunction), Healthy volunteers (Adverse effects of opioids on the gut), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
NCT03087708: Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Terminated
2
50
US
Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
01/21
04/23
2020-003687-10: To evaluate in patients with opioid induced constipation if the use of Naloxegol may improve gastric emptying rate and gastric symptoms

Not yet recruiting
2
50
Europe
Moventig, Tablet, Moventig
UZLeuven, Kyowa Kirin Holdings BV
Opioid induced gastrointestinal dysfunction, gastrointestinal symptoms caused by opioid intake, Diseases [C] - Digestive System Diseases [C06]
 
 
ANTAGOCYST-01, NCT04219046: Evaluation of Naloxegol in the Prevention of POI After Cystectomy

Not yet recruiting
2
102
NA
Naloxégol oxalate, Naloxegol, Placebo oral tablet, Placebo
Institut Paoli-Calmettes
Bladder Cancer, Cystostomy; Complications
09/22
12/22
NCT02813369: Naloxegol Health Outcome Post Authorisation Safety Study

Terminated
N/A
10000
Europe
naloxegol, non-PAMORA laxative
Kyowa Kirin Pharmaceutical Development Ltd
Opioid Induced Constipation
11/21
11/21
NCT02813356: Naloxegol US PMR CV Safety.

Active, not recruiting
N/A
8800
US
naloxegol, non-PAMORA
Valinor Pharma LLC
Opioid Induced Constipation
12/23
12/23
NCT03720613: Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

Recruiting
N/A
34532
US
Naldemedine, Symproic®, Lubiprostone, Amitiza®, Naloxegol, Movantik®
BioDelivery Sciences International, HealthCore, Inc.
Opioid-induced Constipation
11/30
11/30
Aemcolo (rifamycin SV MMX) / Cosmo Pharma, RedHill, Dr Falk
NCT04501380: Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

Enrolling by invitation
2
30
US
AEMCOLO (Rifamycin SV MMX)
Bradley Connor
Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection
12/22
12/22
RIVET, NCT04082780: Rifamycin in Minimal Hepatic Encephalopathy

Completed
2
30
US
Rifamycin SV MMX, Aemcolo, Placebo
Hunter Holmes Mcguire Veteran Affairs Medical Center
Hepatic Encephalopathy, Cirrhosis, Liver
04/23
04/23
NCT04027894: Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Not yet recruiting
2
142
NA
Rifamycin SV MMX, Rifamycin, Placebo to Rifamycin SV-MMX, Placebo
RedHill Biopharma Limited
Traveler's Diarrhea
01/25
12/25
NCT04026984: Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Not yet recruiting
2
142
NA
Rifamycin SV-MMX, Rifamycin, Placebo
RedHill Biopharma Limited
Traveler's Diarrhea
06/25
12/25
clarithromycin/clofazimine/rifabutin (RHB-204) / RedHill
CleaR-MAC, NCT04616924: RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

Terminated
3
12
US
RHB-204, Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg, Placebo
RedHill Biopharma Limited
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
08/23
08/23

Download Options